Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual MeetingNew preclinical efficacy data in liver fibrosis to be presented on November 17 at AASLD - The Liver Meeting ® 2024Cash and cash equivalents of $26.9 million expected to f ...